TRVN


Trevena (TRVN) Stock Roars Back to Life; Analysts Dive In

Shares of Trevena (TRVN) came back to life. The struggling biotech stock took a rare leap upward last week, as well as today, as resolution …

Trevena (TRVN) Stock Is the Latest Biotech Bottle Rocket

It’s a very rewarding trading day for investors in Trevena (TRVN) with shares up over 70%, making the stock Wall Street’s bull of …

Is It Game Over for Trevena (TRVN) Stock?

On Friday, Trevena (TRVN) announced it received a discouraging Complete Response Letter (CRL) from the FDA for its experimental pain drug, Oliceridine. Importantly, …

Trevena (TRVN): The AdCom Vote Was a Lot Closer Than You Think

Some investors might love biotech stocks for their lottery ticket-like returns when a company wins the regulator’s blessing. A lottery ticket, however, costs only …

Trevena (TRVN) Stock Hit with a Downgrade; Shares Tumble Over 10%

In a research note issued today, healthcare analyst Alan Carr of Needham walks investors through this week’s Trevena (TRVN) bloodbath. Shares are down nearly over …

The Bullish Stance on Trevena (TRVN) Comes to an End; Analyst Downgrades the Stock

Tuesday turned out to be a nightmare for shareholders of Trevena (TRVN), as the stock price plummeted 64% in the wake of negative …

Trevena’s (TRVN) Briefing Documents Have Little Read-Across to AcelRx’s (ACRX) Dsuvia, Says Oppenheimer

The Food and Drug Administration (FDA) is scheduled to hold an advisory committee meeting on Friday to review AcelRx’s (ACRX) pain medication Dsuvia. …

Spooked Investors Send Trevena (TVRN) Stock Spiraling as the Company’s Lead Drug Candidate Faces Major Downfall

The US Food and Drug Administration (FDA) puts the needle in the arm of drug company Trevena (TRVN). The agency’s critical briefing documents …

Analysts Bet Trevena’s (TRVN) Pain Management Drug Will Get FDA Approval

Every month brings plenty of catalysts for several biotech stocks. October is no exception.

JMP Highlights Two Biotech Stocks to Consider Ahead of Upcoming FDA Decisions: Trevena (TRVN), Ocular (OCUL)

JMP analysts have profiled two biopharmaceutical firms that they believe are set up to do well in the rest of 2018 and beyond. Both companies are …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts